SSXA1 Inhibitors
SSXA1 inhibitors encompass a group of chemical entities tailored to selectively engage with the SSXA1 enzyme. The interaction between these inhibitors and the enzyme is a finely tuned process, where the molecules are crafted to attach to critical areas within the enzyme structure, such as the active site. This binding is aimed at modulating the enzyme's activity by inducing conformational changes or obstructing the enzyme's ability to bind with its natural substrates. The creation of such inhibitors involves a sophisticated understanding of the enzyme's three-dimensional configuration, which is often determined through advanced scientific techniques, including but not limited to, X-ray crystallography and computational simulations. The goal is to achieve a high degree of specificity to ensure minimal interaction with other proteins and enzymes within the biological system.
The synthesis and refinement of SSXA1 inhibitors is a complex task that integrates elements of organic synthesis, biophysical chemistry, and structural biology. It commences with a thorough investigation of the enzyme's functionality and its participation in cellular processes. Subsequent steps involve designing and synthesizing molecules that can effectively engage with the enzyme. These inhibitors can exhibit a broad spectrum of chemical structures, from relatively simple organic compounds to more elaborate and sizable configurations. The chemical identity of these inhibitors is characterized by their affinity for the enzyme, which is a direct consequence of the intermolecular forces at play, such as electrostatic interactions, hydrogen bonding, and hydrophobic contacts. The potency of an inhibitor is largely dependent on its ability to compete with the natural substrates of the enzyme, and its efficacy is further influenced by its biochemical stability and compatibility within the biological milieu. The design process meticulously evaluates these compounds to ensure optimal interaction with the SSXA1 enzyme.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 leads to the downregulation of the PI3K/Akt signaling pathway. Since SSXA1 activity is modulated by PI3K-dependent phosphorylation, inhibition of PI3K by LY294002 would result in reduced SSXA1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of mitogen-activated protein kinase kinase (MEK), PD98059 blocks the MEK/ERK pathway. If SSXA1 function is regulated by ERK-mediated phosphorylation, PD98059 would indirectly inhibit SSXA1 activity by preventing its phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, which is involved in cellular responses to stress and cytokines. If SSXA1 is activated via p38 MAPK signaling, SB203580 will reduce SSXA1 function by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor, U0126 prevents the activation of MEK1/2 and consequently ERK1/2. By inhibiting this pathway, U0126 could decrease SSXA1 activity if SSXA1 is downstream of ERK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin disrupts the mTORC1 signaling complex. If SSXA1 is part of growth factor signaling pathways that involve mTOR, its activity would be decreased by inhibiting mTOR with Rapamycin. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Similar to LY294002, Wortmannin is a PI3K inhibitor, and it would lead to decreased SSXA1 activity by preventing PI3K-mediated phosphorylation of SSXA1, assuming SSXA1 is a PI3K pathway component. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of c-Jun N-terminal kinase (JNK), SP600125 would inhibit SSXA1 if SSXA1 activation is JNK-dependent, by blocking the JNK signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
As a tyrosine kinase inhibitor, Dasatinib can inhibit Src family kinases. If SSXA1 activity is regulated by Src kinase-mediated phosphorylation, Dasatinib would lead to reduced SSXA1 activity by inhibiting Src kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
This proteasome inhibitor could lead to the accumulation of proteins that negatively regulate SSXA1, thereby indirectly decreasing its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), Thapsigargin causes a rise in cytosolic calcium levels. If SSXA1 activity is calcium-dependent, its function could be inhibited by the perturbation of calcium homeostasis. | ||||||